Introduction and Hypothesis <p>To confirm the performance and safety of the rechargeable sacral neuromodulation system (InterStim™ Micro) through 2-year follow-up, we report results from the fecal incontinence (FI) cohort through 6-month follow-up.</p> Methods <p>Eligible patients were enrolled following successful therapy evaluation and implant. Participants completed bowel diaries and questionnaires at baseline, 3, and 6 months post-implant. The primary objective was improvement in Cleveland Clinic Incontinence Score (CCIS) at 3 months post-implant compared to baseline. Safety was evaluated by collection of reportable adverse events (AE).</p> Results <p>Of 53 patients implanted, 90.6% were female and the mean (± SD) age was 58 ± 11&#xa0;years. There was a statistically significant improvement in CCIS at 3&#xa0;months vs baseline, with a mean change of −4 ± 3.7 (<i>p</i> &lt; 0.001, <i>n</i> = 52). This improvement was maintained at 6&#xa0;months, with a mean change of −4.0 ± 3.58 (<i>n</i> = 52). The mean change in Fecal Incontinence Quality of Life (FIQoL) at 3&#xa0;months was 3.2 ± 2.8 (<i>n</i> = 52) and 3.6 ± 2.9 (<i>n</i> = 53) at 6&#xa0;months. On the Patient Global Impression of Improvement (PGI-I), 94% (<i>n</i> = 52) and 90.6% (<i>n</i> = 53) of participants reported their condition was better at 3- and 6-month follow-up compared to baseline, respectively. The incidence of device-, procedure-, or therapy-related AEs in enrolled participants was 18.9% (10/53); among these was one serious related AE. There were no unanticipated adverse device effects.</p> Conclusions <p>The primary objective of the FI cohort was met, with statistically significant improvement in CCIS and patient-reported outcomes. These data confirm clinical performance and safety through 6 months post-implant.</p> <p>Clinical trial registration: NCT04506866.</p>